<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415126</url>
  </required_header>
  <id_info>
    <org_study_id>ASN007-101</org_study_id>
    <nct_id>NCT03415126</nct_id>
  </id_info>
  <brief_title>A Study of ASN007 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asana BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asana BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is divided into two parts. The first part of the study will test various doses of
      ASN007 to find out the highest safe dose to test in five specific groups. The second part of
      the study will test how well ASN007 can control cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A is a dose escalation study to determine a safe and tolerable dose of ASN007 for
      patients with advanced solid tumors. Part A will also describe how the body works on
      ASN007(pharmacokinetics) and the effects of ASN007 on the body (pharmacodynamics) of ASN007,
      through blood sampling and optional biopsies..

      Part B of the study will enroll patients with particular tumor types and genetic mutations
      for treatment at the Recommended Phase 2 Dose. Part B will enroll patients in five groups of
      fifteen patients each:

      Group 1: Patients with metastatic BRAF mutated melanoma Group 2: Patients with metastatic
      NRAS and HRAS mutated solid tumors Group 3: Patients with metastatic KRAS mutated colorectal
      cancer (CRC) Group 4: Patients with metastatic KRAS mutated non-small cell lung cancer
      (NSCLC) Group 5: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Patients
      with melanoma will be required to have pre-dose and post-dose biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Determine the maximum tolerated dose (MTD) of ASN007</measure>
    <time_frame>First 21 days</time_frame>
    <description>The MTD will be determined by evaluating the number of subjects with treatment related dose limiting toxicity. This is the primary endpoint of Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.</measure>
    <time_frame>First 6 months</time_frame>
    <description>This is the primary endpoint for Part B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculate the pharmacokinetic area under the plasma concentration (AUC) of ASN007</measure>
    <time_frame>First 21 days</time_frame>
    <description>Calculate the amount of ASN007 in the bloodstream</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate the maximum plasma concentration (Cmax) at steady state.</measure>
    <time_frame>First 21 days</time_frame>
    <description>Calculate the maximum amount of ASN007 in the bloodstream</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate the terminal elimination rate (T 1/2).</measure>
    <time_frame>First 21 days</time_frame>
    <description>Calculate how fast ASN007 leaves the body</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate the change from baseline in the intensity of phosphorylated ribosomal S6 kinase (RSK) found in tumor biopsies.</measure>
    <time_frame>Through the study, average 6 months</time_frame>
    <description>Evaluate the effect of ASN007 on biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate the change from baseline in the intensity of Ribosomal S6 Kinase (RSK) found in circulating tumor cells.</measure>
    <time_frame>Through the study, average 6 months</time_frame>
    <description>Evaluate the effect of ASN007 on biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the change from baseline in the amount of circulating tumor DNA</measure>
    <time_frame>Every 8 weeks for the first 24 weeks, then every 12 weeks for up to 1 year</time_frame>
    <description>Evaluate the effect of ASN007 on biomarkers</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cancer</condition>
  <condition>Malignancy</condition>
  <condition>Neoplasia</condition>
  <condition>Neoplasm</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Colon Cancer</condition>
  <condition>Colonic Neoplasms</condition>
  <condition>Colon Cancer Liver Metastasis</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Metastatic Colon Cancer</condition>
  <condition>Metastatic Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreas Adenocarcinoma</condition>
  <condition>Pancreas Neoplasm</condition>
  <condition>Metastatic Nonsmall Cell Lung Cancer</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>ASN007 ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive escalating doses of ASN007 to identify the best dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN007 RD: KRAS mutant Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN007 RD: NRAS mutant Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN007 RD: KRAS mutant metastatic CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with KRAS mutant CRC will receive the recommended dose from Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN007 RD: KRAS mutant NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with KRAS mutant NSCLC will receive the recommended dose from Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN007 RD: Metastatic Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASN007: ascending doses</intervention_name>
    <description>Oral drug for the treatment of advanced solid tumors</description>
    <arm_group_label>ASN007 ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASN007 RD</intervention_name>
    <description>Oral drug for the treatment of advanced solid tumors</description>
    <arm_group_label>ASN007 RD: KRAS mutant Melanoma</arm_group_label>
    <arm_group_label>ASN007 RD: NRAS mutant Melanoma</arm_group_label>
    <arm_group_label>ASN007 RD: KRAS mutant metastatic CRC</arm_group_label>
    <arm_group_label>ASN007 RD: KRAS mutant NSCLC</arm_group_label>
    <arm_group_label>ASN007 RD: Metastatic Pancreatic Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to any study-related procedure being
             performed;

          -  Male or non-pregnant, non-lactating female patient at least 18 years of age at the
             time of consent;

          -  Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B)

          -  Histologically or cytologically confirmed

          -  advanced or metastatic solid tumor (Part A)

          -  Group 1: BRAF mutant melanoma (Part B)

          -  Group 2: NRAS or HRAS mutant solid tumors(Part B)

          -  Group 3: KRAS mutant CRC.(Part B)

          -  Group 4: KRAS mutant NSCLC (Part B)

          -  Group 5: Pancreatic Ductal Adenocarcinoma (Part B)

          -  Progressive disease after failure of or intolerant to all available standard systemic
             treatments that have shown a documented benefit in overall survival for their
             respective tumor type.

          -  Measurable or evaluable disease per RECIST v1.1

          -  Screening hematology values of the following:

          -  absolute neutrophil count ≥ 1000/μL,

          -  platelets ≥ 100,000/μL,

          -  hemoglobin ≥ 9 g/dL

          -  Screening chemistry values of the following:

          -  alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of
             the normal (ULN),

          -  total bilirubin ≤ 1.5 × ULN,

          -  creatinine ≤ 1.5 × ULN,,

          -  albumin ≥ 2.8 g/dL.

          -  Screening heart function lab test

          -  creatinine kinase - MB, troponin-I, and troponin-T within normal limits

          -  Subject is willing and able to comply with all protocol required visits and
             assessments, including biopsy if assigned.

        Exclusion Criteria:

          -  Prior treatment with ASN007 or another ERK1/2 inhibitor

          -  Known hypersensitivity to ASN007 or its excipients;

          -  Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant
             melanoma (Group 1)

          -  Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of
             start of study treatment (Day1), or 5 half-lives, whichever is shorter.

          -  Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within
             3 weeks prior to Day 1 of treatment.

          -  Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of
             treatment

          -  Failure to recover from major surgery or traumatic injury within 4 weeks or minor
             surgery within 2 weeks prior to Day 1 of treatment.

          -  History of or current evidence / risk of retinal vein occlusion (RVO) central serous
             retinopathy (CSR), or glaucoma with intraocular pressures ≥ 21 mmHg or other
             pre-existing ocular conditions that may put the patient at risk for ocular toxicities

          -  Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous
             meningitis (Part A). Patients may be enrolled with CNS metastasis in certain
             circumstances in Part B.

          -  Clinically significant heart disorders including an ejection fraction of &lt; 50%

          -  Other serious uncontrolled conditions such as fungal, bacterial or viral infection;
             HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,

          -  Any other condition that might place the patient at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Asana BioSciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>908-698-4973</phone>
    <email>penny.bristow@asanabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Director</last_name>
    <phone>908-332-9119</phone>
    <email>sarper.toker@asanabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Drew Rasco, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS mutant</keyword>
  <keyword>NRAS mutant</keyword>
  <keyword>BRAF mutant</keyword>
  <keyword>HRAS mutant</keyword>
  <keyword>ERK 1/2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

